E-cadherin Expression in Children with Acute Leukemia and Its Clinical Significance.
10.19746/j.cnki.issn.1009-2137.2019.02.005
- Author:
Bin-Xia BAO
1
;
Xi-Zhou AN
1
;
Peng-Fei LI
1
;
Yong-Jing LI
1
;
Ying-Hui CUI
1
;
Xue TANG
1
;
Qi-Hui LIU
1
;
Yan-Ni HU
1
;
Wei LIU
1
;
Shao-Yan LIANG
1
;
Jie YU
2
Author Information
1. Department of Hematology & Oncology, Childhren＇s Hospital Affiliated to Chongqing Medical University; Key Laboratory of Child Development and Disorders of Ministry of Education; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
2. Department of Hematology & Oncology, Childhren＇s Hospital Affiliated to Chongqing Medical University; Key Laboratory of Child Development and Disorders of Ministry of Education; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China,E-mail: 1808106657@qq.com.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Bone Marrow;
Cadherins;
Child;
Humans;
Leukemia, Myeloid, Acute;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
- From:
Journal of Experimental Hematology
2019;27(2):339-347
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the correlation of E-cadherin expression level with the clinical characterastics in children with acute leukemia (AL), and to explore the possible regulatory mechanism.
METHODS:Real-time quantitative RT-PCR was applied to detect the expression level of E-cadherin in bone marrow samples from 135 child patients diagnosed as AL, and its relevance with clinical indicators was statistically analyzed. The expression levels of E-cadherin, β-catenin, and Akt/p-Akt were detected by using Western blot. The bone marrow samples from 22 children with non-malignant hematological diseases were used as controls.
RESULTS:The expression level of E-cadherin significantly decreased in newly diagnosed patients with all 3 types of AL as compared with bone marrow samples from control group (P<0.01). In B-ALL group, compared with standard risk group, E-cadherin expression level significantly decreased in intermediate risk group (P<0.05). Moreover,the expression level of E-cadherin mRNA was also reduced in splenomegaly group (P<0.01). However, the correlation of E-cadherin level with clinical characteristics was not found in T-ALL and AML (P>0.05). The expression level of E-cadherin in the patients from Common-B-ALL group was higher than B-ALL patients with other immunophenotypes (P<0.01), while no significant difference was found among patients grouped by FAB classification. By the correlation analysis of measured data, lower E-cadherin expression level was found to be related with high WBC count and serum lactic dehydrogenase level (LDH) (r=-0.419, r=-0.269), but with low blood platelet count in B-ALL (r=0.335). In T-ALL, expression of E-cadherin was found to be negatively correlated with LDH and percentage of immature cells in the bone marrow (r=-0.567, r=-0.557). In addition, the lower expression of E-cadherin was also found to be related with WBC count and percentage of immature cells in the bone marrow in newly diagnosed AML patients (r=-0.368, r=-0.391). Compared with control group, the expression of E-cadherin was down-regulated significantly (P<0.01), while β-catenin, Akt significantly was up-regulated in 3 types of AL patients (P<0.01). The expression of p-Akt and p-Akt/Akt was up-regulated significantly in T-ALL (P<0.01).
CONCLUSION:Lower expression of E-cadherin is related factor of unfavourable prognosis in children with acute leukemia. The expression deficiency or down-regulation of E-cadherin may activate Wnt/β-catenin and PI3K/ Akt signaling pathways to promote the genesis and progress of haematological malignancies, thus resulting in a series of malignant biological behaviors in cells. E-cadherin may be a new prognostic indicator for pediatric acute leukemia, thus to guide individualized hemotherapy.
